Radiotherapy research priorities for the UK

Clinical Oncology

Volumn 22, Issue 8, 2010, Pages 707-709

  Maughan, T S ^a   Illidge, T M ^b   Hoskin, P ^c   McKenna, W G ^d   Brunner, T B ^d   Stratford, I J ^e   Harrington, K J ^f   Plummer, R ^g   Billingham, L J ^h   Nutting, C ^f   Burnet, N G ⁱ   Mackay, R I ^b   Oliver, A ^j   Young, C ^j   Chan, C S K ^j  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c MOUNT VERNON HOSPITAL   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^g NEWCASTLE UNIVERSITY   (United Kingdom)

^h UNIVERSITY OF BIRMINGHAM   (United Kingdom)

ⁱ UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^j INSTITUTE OF CANCER RESEARCH   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; GEMCITABINE; NELFINAVIR;

CANCER RADIOTHERAPY; CLINICAL TRIAL; EDITORIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL RESEARCH; PANCREAS CANCER; PRIORITY JOURNAL; RADIATION INJURY; RADIOBIOLOGY; RADIOTHERAPY; UNITED KINGDOM;

GREAT BRITAIN; HUMANS; RADIOTHERAPY; RESEARCH;

EID: 77956263564     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2010.03.006     Document Type: Editorial

References (8)

1. Harrington K., Jankowska P., Hingorani M. Molecular biology for the radiation oncologist: the 5Rs of radiobiology meet the hallmarks of cancer. Clin Oncol 2007, 8:561-571.
2. O'Shaughnessy J., Osborne C., Pippen J., et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. J Clin Oncol 2009, 27(Suppl.):18s. (abstract 3).
3. Tutt A., Robson M., Garber J., et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J Clin Oncol 2009, 27(Suppl.):18s. (abstract CRA501).
4. Calabrese C.R., Almassy R., Barton S., et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 2004, 96:56-67.
5. Tentori L., Portarena I., Graziani G. Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors. Pharmacol Res 2002, 45:73-85.
6. Nutting C., A'Hern R., Rogers M.S., et al. First results of a phase III multi-centre randomised controlled trial of intensity modulated (IMRT) vs conventional radiotherapy (RT) in head and neck cancer (PARSPORT: ISRCTN48243537). Proc ASCO J Clin Oncol 2009, 27:18s. 799s, LBA6006.
7. Gills J.J., Lopiccolo J., Tsurutani J., et al. Nelfinavir, a lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res 2007, 13(17):5183-5194.
8. Brunner T.B., Geiger M., Grabenbauer G.G., et al. Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer. J Clin Oncol 2008, 26(16):2699-2706.